2026-05-21T23:20:04Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/188162024-09-21T23:53:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Garcia de Lucas, Maria Dolores author Miramontes-González, Jose Pablo author Avilés-Bueno, Beatriz author Jiménez-Millán, Ana Isabel author Rivas-Ruiz, Francisco author Pérez-Belmonte, Luis M author 2022-09-16 To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals. An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c 5%. After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use. 10.3389/fendo.2022.995646 1664-2392 Frontiers in endocrinology http://hdl.handle.net/10668/20571 36187123 http://hdl.handle.net/20.500.12105/18816 HbA1c T2DM body weight once-weekly semaglutide real-world use Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.